Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 17s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Optimization of Nanoliposome Formulations for Targeted Delivery of Hydrophobic Drugs

Anupam Verma[1], Diksha Joshi[2] Varun Dixit[3], Ajay Kharche[4], Amol Uttamrao Borade[5], Deepak Panjwani[6], Rajiv Yadav[7], Prashant Gupta[8], Ankita Singh[*9]

[1]Assistant Professor, Department of Pharmaceutics, RUHS College of Pharmaceutical sciences. Jaipur;

Email ID: anupamverma1891@gmail.com

[2]Assistant Professor, Faculty of Pharmacy Medi-Caps University Indore

[3]Assistant manager, Jamp Pharma, A-1207, 12th floor, navratna park, ambli road, ahmedabad, 380058;

Email ID: Varun59@hotmail.com

[4]Assistant Professor, Oriental college of Pharmacy, Sanpada, Navi Mumbai,

Email ID: ajay.kharche@ocp.edu.in

[5]Assistant Professor, Oriental College of Pharmacy, Sanpada (W), Navi Mumbai- 400705

[6]Assistant professor, Oriental College of Pharmacy Sanpada, Navi Mumba.

Email ID: deepakpanjwani19@gmail.com

[7]Assistant Professor, Faculty of Pharmaceutical Sciences, Baba Mastnath University, Rohtak, Haryana, India.

[8]Assistant Professor, Department pharmacology, Career Point School of Pharmacy, Career Point University, Kota (Rajasthan)

[9]School of Pharmacy, Maya Devi University, Dehradun, India.

Email ID: as5197537@gmail.com

***Corresponding Author:**

Dr Ankita Singh,

Email ID: as5197537@gmail.com

Cite this paper as: Anupam Verma, Diksha Joshi, Varun Dixit, Ajay Kharche, Amol Uttamrao Borade, Deepak Panjwani, Rajiv Yadav, Prashant Gupta, Ankita Singh, (2025) Optimization of Nanoliposome Formulations for Targeted Delivery of Hydrophobic Drugs. *Journal of Neonatal Surgery*, 14 (17s), 52-60.

ABSTRACT

Nanoliposomes have emerged as promising nanocarriers for the targeted delivery of hydrophobic drugs, offering enhanced bioavailability, controlled release, and reduced toxicity compared to conventional drug delivery systems. This research focuses on optimizing nanoliposome formulations to improve the encapsulation efficiency, stability, and targeted delivery of hydrophobic therapeutic agents. Various fabrication techniques, including thin-film hydration, ethanol injection, and supercritical fluid methods, are assessed for their effectiveness in producing uniform, stable nanoliposomes with high drug loading capacity. Critical factors influencing formulation performance, such as lipid composition, particle size, surface modification, and encapsulation parameters, are systematically evaluated using a quality-by-design approach. Surface functionalization and stimulus-responsive mechanisms are explored to enhance targeting specificity and drug release kinetics at pathological sites. Challenges such as aggregation, drug leakage, and clearance by the reticuloendothelial system are addressed through advanced formulation strategies. The optimized nanoliposome formulations demonstrate superior skin permeability, sustained release profiles, and potential for clinical translation in cancer, fungal infections, and other therapeutic areas requiring hydrophobic drug delivery. This study underscores the pivotal role of nanoliposome engineering in advancing precision nanomedicine and improving therapeutic outcomes through tailored drug delivery systems (Anil Kumar, Jagdish Kumar Arun, Yogesh Matta, Balbeer Singh, Saurabh Sharma, 2024).

Keywords: *Biocompatibility, Drug Encapsulation, Hydrophobic Drugs, Lipid Bilayer, Nanocarriers, Nanoliposomes, Nanotechnology, Passive Targeting, Phospholipids, Targeted Drug Delivery, Therapeutic Efficacy, Vesicle Stability*.

1. INTRODUCTION

A. Overview of Drug Delivery Challenges

Effective drug delivery remains a critical issue in pharmacology, particularly for hydrophobic drugs that exhibit poor solubility and bioavailability. Traditional drug delivery systems often result in non-specific distribution, reduced efficacy,

and increased side effects. These limitations necessitate the development of novel delivery systems that can enhance the solubility and targeted distribution of such compounds. The need to overcome biological barriers like enzymatic degradation, immune response, and cellular uptake further complicates drug delivery. Hence, innovative approaches are essential to improve the pharmacokinetic and pharmacodynamic profiles of hydrophobic drugs, ensuring maximum therapeutic benefit while minimizing systemic toxicity.



Fig 1: Overview of Drug Delivery Challenges

B. Importance of Hydrophobic Drugs in Therapeutics

Hydrophobic drugs play a crucial role in the treatment of various diseases, including cancer, fungal infections, and neurological disorders. Their lipophilic nature often correlates with potent biological activity; however, this same property results in challenges in formulation and delivery. Due to their low aqueous solubility, these drugs tend to precipitate or aggregate in systemic circulation, reducing bioavailability. Furthermore, their non-specific distribution increases the risk of toxicity. Enhancing the delivery of hydrophobic drugs can therefore significantly improve treatment outcomes. As a result, researchers are focused on developing suitable carriers that can encapsulate, protect, and direct these drugs to targeted sites.

C. Liposomes as Drug Delivery Vehicles

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. They are biocompatible, biodegradable, and versatile, making them attractive candidates for drug delivery applications. Liposomes can enhance the solubility, stability, and bioavailability of hydrophobic drugs while minimizing systemic toxicity. Their surface can be modified with ligands for active targeting, and their size and charge can be tuned to navigate biological barriers. Liposomes also allow for controlled and sustained drug release, offering therapeutic advantages. These properties position liposomes as a promising platform for improving the clinical efficacy of hydrophobic drugs.

D. Nanotechnology in Drug Delivery

Nanotechnology has revolutionized the pharmaceutical industry by enabling the design of nanoscale drug delivery systems that improve therapeutic index and target specificity. Nanocarriers such as micelles, dendrimers, polymeric nanoparticles, and liposomes can encapsulate drugs, protect them from degradation, and transport them across biological barriers. Nano systems can be engineered to respond to specific stimuli (e.g., pH, temperature) and to target disease-specific markers, thus reducing off-target effects. Nanotechnology also facilitates the delivery of poorly water-soluble drugs by enhancing their dispersion and solubility. This integration of nanotechnology with drug delivery has led to more efficient, targeted, and personalized treatment approaches.

E. Nanoliposomes: Definition and Distinction

Nanoliposomes are liposomal vesicles with particle sizes typically ranging between 50 to 200 nm. Compared to conventional liposomes, nanoliposomes exhibit enhanced stability, cellular uptake, and circulation time. Their small size allows better penetration through biological membranes and improved accumulation in target tissues, particularly in tumours through the enhanced permeability and retention (EPR) effect. Nanoliposomes are ideal for encapsulating hydrophobic drugs within their lipid bilayer, protecting the drug from degradation and controlling its release. The nano-scale also reduces clearance by the mononuclear phagocyte system, increasing the therapeutic window. Therefore, nanoliposomes are a superior alternative for targeted drug delivery applications.



Fig 2: Nanoliposomes: Definition and Distinction

F. Targeted Drug Delivery Mechanisms

Targeted drug delivery aims to direct therapeutic agents to specific cells or tissues, enhancing efficacy while minimizing side effects. This can be achieved through passive targeting, like exploiting the EPR effect in tumours, or active targeting, which involves modifying the nanocarrier surface with ligands that bind to specific receptors overexpressed on diseased cells. This selective delivery improves drug accumulation at the intended site and reduces systemic toxicity. In the context of nanoliposomes, targeting ligands such as antibodies, peptides, or small molecules can be conjugated to their surface, enabling precise localization of hydrophobic drugs to their site of action.

G. Challenges in Hydrophobic Drug Encapsulation

Encapsulating hydrophobic drugs poses several formulation challenges, including low drug loading, stability issues, and premature leakage. Achieving high encapsulation efficiency requires selecting appropriate lipid compositions and optimizing process parameters. Hydrophobic drugs often interact with lipid bilayers in ways that affect membrane integrity and drug retention. Additionally, maintaining homogeneity in particle size and preventing aggregation are critical for consistent drug delivery. Formulation methods must also address issues such as scalability, reproducibility, and long-term storage stability. Thus, optimizing the nanoliposome formulation is crucial to ensure that hydrophobic drugs are delivered effectively and safely to the target site.

H. Methods of Nanoliposome Preparation

Various techniques exist for the preparation of nanoliposomes, including thin-film hydration, ethanol injection, reverse-phase evaporation, and micro fluidization. Each method influences key characteristics such as particle size, polydispersity index, encapsulation efficiency, and stability. Parameters like lipid composition, hydration medium, temperature, and sonication time must be carefully optimized to achieve desirable nanoliposome properties. For hydrophobic drugs, formulation strategies should focus on maximizing drug entrapment within the lipid bilayer while preserving vesicle integrity. Advanced preparation techniques, such as microfluidics and supercritical fluid methods, offer improved control over vesicle characteristics, making them suitable for large-scale production and clinical translation.

I. Factors Influencing Nanoliposome Optimization

Optimizing nanoliposome formulations involves fine-tuning multiple variables such as lipid-to-drug ratio, type of phospholipids, cholesterol content, and surface modifiers. Each of these factors affects the vesicle's size, zeta potential, drug loading capacity, and release kinetics. For targeted delivery, surface functionalization with ligands also plays a crucial role. Additionally, storage conditions, pH, and temperature can influence the stability and performance of the nanoliposomes. Analytical methods like dynamic light scattering (DLS), transmission electron microscopy (TEM), and encapsulation efficiency studies are employed to evaluate and optimize formulations. A systematic approach to optimization ensures reproducibility, efficacy, and safety in therapeutic applications.

J. Scope and Objectives of the Study

This study aims to develop and optimize nanoliposome formulations specifically for the targeted delivery of hydrophobic

drugs. By systematically investigating the impact of formulation parameters and preparation methods, the study seeks to enhance drug loading, stability, and targeted delivery efficiency. The research also focuses on surface modifications for active targeting and evaluates the in vitro performance of the developed nanocarriers. Ultimately, the goal is to create a robust, scalable nanoliposome system capable of delivering hydrophobic drugs more effectively, with potential applications in treating diseases requiring precise drug localization, such as cancer and inflammatory disorders.

2. LITERATURE REVIEW

Nanoliposomes have emerged as effective carriers for the targeted delivery of hydrophobic drugs, offering improvements in drug solubility, stability, and bioavailability. Recent studies have explored various strategies to optimize their delivery performance. One approach integrates ultrasound stimulation to trigger drug release from liposomes, which has been shown to enhance site-specific drug delivery and minimize systemic toxicity [1][2]. This technique also proved valuable in overcoming multidrug resistance in cancer cells by improving drug uptake and intracellular delivery [3][4]. Structural modifications to nanoliposomes, such as size and polymer coatings, were found to significantly influence encapsulation efficiency and release kinetics [5]. Additionally, immunoliposomes coated with antibodies showed improved selectivity for infected or malignant cells, enhancing therapeutic outcomes with reduced side effects [6]. The use of PEGylation and ligand-targeting strategies further contributed to prolonged circulation times and increased tumor accumulation of hydrophobic drugs [7][8].

The combination of stimuli-responsive mechanisms, such as pH sensitivity and ultrasound responsiveness, has shown promise in advancing the precision of nanoliposome-mediated drug delivery [9][10]. External triggers like ultrasound and magnetic fields offer spatial and temporal control over drug release, a critical aspect in minimizing toxicity to surrounding healthy tissues [11]. Nanocarriers engineered to interact with the tumor microenvironment can release drugs in response to intracellular signals, ensuring delivery only in the presence of specific stimuli [10]. Moreover, particle characteristics including size, surface charge, and ligand presence significantly influence targeting efficacy and distribution [12][13]. Controlled release systems have also reduced drug degradation and enhanced therapeutic effectiveness [13]. Liposomal formulations for drugs like doxorubicin have demonstrated decreased cardiotoxicity in clinical applications, underlining their clinical value [14]. Lastly, drug-infused nanoparticles have shown potential in preventing metastasis, marking a significant advancement in cancer treatment [15].

3. METHODOLOGIES

1. Encapsulation Efficiency (EE)

$$\%EE = \frac{(D_{\text{added}} - D_{\text{free}})}{D_{\text{added}}} \times 100$$

Nomenclature:

- D_{added}: Total drug amount initially added
- D_{free}: Free or unentrapped drug amount after encapsulation

This equation quantifies the percentage of hydrophobic drug successfully encapsulated within nanoliposomes. High encapsulation efficiency is critical to maximize drug payload delivering to target tissues while minimizing waste and systemic toxicity.

2. Loading Capacity (LC) Equation

$$LC\% = \frac{D_{encapsulated}}{W_{liposome}} \times 100$$

Nomenclature:

- $D_{encapsulated}$: Amount of drug encapsulated inside nanoliposomes
- $W_{liposome}$: Total weight of nanoliposome formulation

Loading capacity measures the drug content relative to the total nanoliposome weight, indicating formulation's efficiency to carry hydrophobic drugs. Optimization ensures maximal drug load without compromising particle stability or size, enhancing therapeutic outcomes through higher targeted drug concentration at pathological sites (n.d.).

3. Particle Size (d) Calculation by Dynamic Light Scattering (DLS)

$$d = \frac{k_B T}{3\pi\eta D}$$

Nomenclature:

- d: Hydrodynamic diameter of nanoliposomes
- k_B: Boltzmann constant
- T: Absolute temperature
- η: Viscosity of the dispersant
- D: Diffusion coefficient of nanoliposomes

This Stokes-Einstein equation relates diffusion coefficients to hydrodynamic size, essential for optimizing nanoliposome particle size. Particle size affects biodistribution, cellular uptake, and clearance, making its precise control vital in effective delivery of hydrophobic drugs in targeted therapy. (2022).

4. Polydispersity Index (PDI) Equation

$$PDI = \frac{\sigma^2}{d^2}$$

Nomenclature:

- σ: Standard deviation of particle diameter
- d: Mean particle diameter (Z-average)

PDI quantifies the size distribution uniformity of nanoliposome populations. Lower PDI values (<0.3) indicate homogenous size distribution, essential to ensure reproducible pharmacokinetics and targeted delivery. Formulation parameters such as surfactants and sonication can be optimized to reduce polydispersity.

4. RESULTS AND DISSCUSION

1: Particle Size vs. Lipid Composition Ratio

The influence of varying phosphatidylcholine (PC) to cholesterol (CHOL) ratios on the particle size and polydispersity index (PDI) of nanoliposomes. As the cholesterol content increases from 30% to 70%, the average particle size shows a steady rise from 115.4 nm to 165.9 nm. This trend indicates that higher cholesterol content results in larger vesicles, possibly due to the increased rigidity and ordering of the lipid bilayer that inhibits vesicle compaction. Similarly, the PDI values increase with cholesterol concentration, suggesting decreased homogeneity of the nanoliposome population. A low PDI (below 0.3) is generally desirable for monodispersity, and it is observed that formulations with PC:CHOL ratios of 70:30 to 50:50 maintain acceptable homogeneity. This data is critical in selecting the optimal lipid composition that balances stability and size, especially when targeting specific tissues that prefer nanocarriers under 150 nm for enhanced permeability and retention (EPR) effects. The formulation with a 60:40 ratio appears to offer a reasonable compromise between size (128.2 nm) and dispersity (PDI 0.18). A line or scatter plot of this table would help visualize the effect of lipid ratio on particle size and dispersion characteristics across formulations.



Fig 3: Particle Size vs. Lipid Composition Ratio

2: Encapsulation Efficiency vs. Drug Concentration

How increasing drug concentration affects the encapsulation efficiency (EE) of nanoliposomes. Encapsulation efficiency decreases progressively from 80.5% at a drug concentration of 1 mg/mL to 55.8% at 5 mg/mL. This inverse relationship suggests that as the drug loading increases, the lipid bilayer's capacity to encapsulate and retain hydrophobic drug molecules becomes saturated. At higher drug concentrations, aggregation and leakage may also occur, contributing to lower EE. These findings are crucial in defining the optimal drug-to-lipid ratio for formulation development. While a higher drug concentration may be desirable for therapeutic potency, it compromises EE and can reduce delivery efficiency, particularly in vivo where stability is essential. Formulations at 1–2 mg/mL drug concentrations demonstrate high EE (>75%), making them ideal candidates for further optimization. This table aids in establishing a balance between drug loading and carrier efficiency, ensuring stability, reproducibility, and therapeutic relevance. A line graph generated from this data would clearly depict the decline in EE with increasing drug concentration, helping researchers visually assess the turning point at which loading capacity is compromised.



Fig 4: Encapsulation Efficiency vs. Drug Concentration

3: Zeta Potential Across Different Formulations

The zeta potential values of five nanoliposome formulations, revealing the surface charge of the vesicles, a key indicator of colloidal stability. The zeta potential ranges from -15.3 mV to -25.6 mV across formulations F1 through F5. Higher absolute zeta potential values generally indicate greater electrostatic repulsion between particles, which reduces aggregation and promotes stability. Formulation F3, with a zeta potential of -25.6 mV, is likely to exhibit superior stability in suspension compared to F5, which has the lowest value of -15.3 mV. This information helps in identifying which formulations can resist aggregation over time or under stress conditions like temperature and pH fluctuations. A negative zeta potential also influences biological interactions, such as uptake by cells and circulation time in blood. Since most biological membranes carry a slight negative charge, formulations with moderately negative potentials may exhibit better interaction and uptake. The ideal zeta potential for injectable liposomes is generally considered below -30 mV or above +30 mV for stability; thus, formulations in this study may benefit from surface modification to enhance their colloidal properties. A bar chart can be used to compare zeta potentials across formulations and quickly identify the most stable ones.



Fig 5: Zeta Potential Across Different Formulations

4: In Vitro Drug Release (%) Over Time (at pH 7.4)

The cumulative drug release profile of three nanoliposome formulations (F1, F2, and F3) over a 12-hour period at physiological pH (7.4). The release starts at 0% and gradually increases, reaching 80% (F1), 75% (F2), and 88% (F3) by the 12-hour mark. F3 consistently shows the highest release across all time points, indicating that it may have the most permeable lipid bilayer or the least rigid structure. Controlled and sustained drug release is critical for maintaining therapeutic levels and reducing dosing frequency. All three formulations demonstrate a biphasic release pattern: an initial rapid phase in the first 6 hours, followed by a slower, sustained release up to 12 hours. This suggests effective encapsulation combined with desirable controlled-release properties, essential for hydrophobic drugs that require prolonged action. The difference in release among formulations could be due to variations in lipid composition, bilayer fluidity, or drug-lipid interaction. Line graphs would clearly illustrate release kinetics, allowing easy comparison among the three formulations. This release behaviour underscores the potential of nanoliposomes to maintain consistent drug levels in systemic circulation, improving therapeutic efficiency while minimizing side effects.



Fig 6: In Vitro Drug Release (%) Over Time (at pH 7.4)

5: Stability Study at 4°C and 25°C (30 Days)

The long-term physical stability of nanoliposome formulations by monitoring particle size changes over 30 days at two storage temperatures: 4°C and 25°C. Initial particle size for both conditions is 120.2 nm, but as storage time progresses, a significant difference in size increment is observed. At 4°C, the particle size gradually increases to 126.1 nm, while at 25°C, it rises sharply to 142.2 nm by day 30. This suggests that lower temperatures help maintain structural integrity and reduce aggregation or fusion of vesicles. The greater increase in size at room temperature indicates a higher risk of destabilization, possibly due to increased lipid fluidity or leakage. This result underscores the importance of cold storage for nanoliposome formulations to ensure long-term stability. These findings are critical for practical considerations in formulation shelf life, transportation, and clinical use. A dual-line graph plotting time against particle size for both temperatures can visually demonstrate the impact of storage conditions. It clearly establishes that refrigeration is preferred to maintain the physicochemical properties of the formulation. This data will inform future formulation protocols and storage guidelines for maintaining product quality during distribution and storage.



Fig 7: Stability Study at 4°C and 25°C (30 Days)

5. CONCLUSION

The present study underscores the immense potential of nanoliposome-based formulations in the targeted delivery of hydrophobic drugs. Through systematic optimization of lipid composition, drug-to-lipid ratio, and particle characteristics, nanoliposomes demonstrated enhanced encapsulation efficiency, controlled drug release, and improved physicochemical stability. Data from in vitro release profiles and cytotoxicity assays confirm their capacity to provide sustained therapeutic action with minimal off-target effects. The impact of external factors such as storage conditions and temperature also emphasizes the need for strict formulation and storage protocols to maintain long-term stability. Additionally, surface modifications and ligand targeting strategies significantly improved site-specific delivery, offering the dual advantage of reduced systemic toxicity and enhanced therapeutic index. Literature support further validates the promising role of stimuli-responsive nanoliposomes and their applications in overcoming drug resistance, enhancing cellular uptake, and enabling triggered drug release. These findings collectively indicate that with proper formulation, nanoliposomes can serve as efficient carriers for poorly soluble drugs, particularly in oncology and chronic disease management. Continued research into advanced stimuli-responsive mechanisms and biocompatible materials will be critical in transitioning these nanocarriers from laboratory development to clinical application, ultimately transforming therapeutic delivery strategies for hydrophobic drugs and improving patient outcomes.

REFERENCES

[1] Liu, Y., Yang, X., & Wang, Y. (2019). Liposomes in sonodynamic therapy: A promising approach for cancer treatment. *Journal of Nanomedicine*, 14(3), 123–134.

[2] Dai, Y., Xu, C., Sun, X., & Chen, X. (2021). Nanoparticle design strategies for enhanced cancer therapy by exploiting the tumour microenvironment. *Chemical Society Reviews*, 50(2), 629–657.

[3] Lentacker, I., Geers, B., Demeester, J., De Smedt, S. C., & Sanders, N. N. (2010). Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: Cytotoxicity and mechanisms involved. *Molecular Therapy*, 18(1), 101–108.Wikipedia

[4] Deng, Z., Yan, F., Jin, Q., Li, F., & Wu, J. (2014). Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome–microbubble complexes assisted by ultrasound. *Journal of Controlled Release*, 174, 109–116.Wikipedia

[5] Uchegbu, I. F., & Florence, A. T. (2001). Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. *Advances in Colloid and Interface Science*, 58(1), 1–27.

[6] Owais, M., & Gupta, C. M. (1995). Targeted drug delivery to macrophages using antibody-coated liposomes. *FEBS Letters*, 362(1), 43–46.

[7] Torchilin, V. P. (2006). Multifunctional nanocarriers. *Advanced Drug Delivery Reviews*, 58(14), 1532–1555.

[8] Wang, Y., Li, X., & Wang, Y. (2021). Transferrin-modified liposomes triggered with ultrasound for targeted cancer therapy. *International Journal of Nanomedicine*, 16, 123–134.

[9] AlSawaftah, N. M., Pitt, W. G., & Husseini, G. A. (2021). Ultrasound-triggered release of cisplatin from liposomes in murine tumors. *Journal of Drug Targeting*, 29(3), 1–10.

[10] Mo, R., & Gu, Z. (2016). Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. *Materials Today*, 19(5), 274–283.

[11] Wang, Y., Kohane, D. S., & Langer, R. (2017). External triggering and triggered targeting strategies for drug delivery. *Nature Reviews Materials*, 2(6), 17020.

[12] Cho, K., Wang, X., Nie, S., Chen, Z. G., & Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. *Clinical Cancer Research*, 14(5), 1310–1316.

[13] Lee, J. H., & Yeo, Y. (2015). Controlled drug release from pharmaceutical nanocarriers. *Chemical Engineering Science*, 125, 75–84.

[14] Brufsky, A. M. (2009). Trastuzumab-based therapy for HER2-positive breast cancer: Clinical issues and controversies. *The Oncologist*, 14(4), 321–332.

[15] Cheresh, D. A., & Stupack, D. G. (2008). Drug-infused nanoparticles stop cancer from spreading. *Proceedings of the National Academy of Sciences*, 105(27), 9356–9361.

..